THE WHAT? US drug maker Viatris is said to be considering a sale of its US$3 billion European consumer-health assets, according to a report by Bloomberg. 

THE DETAILS The company is working with investment bank Jefferies Financial Group to find potential buyers, according to sources who asked not to be named. 

Shares in Viatris rose 4.7 percent this week. 

THE WHY? According to the sources, the assets could encourage interest from large private equity firms that have existing other-the-counter businesses, or strategic buyers looking to grow their business in the region.